Scholarlink

<p>Elinzanetant (Lynkuet™) is a non-hormonal, small-molecule neurokinin 1 (NK<sub>1</sub>) and 3 (NK<sub>3</sub>) antagonist being developed by Bayer for the treatment of vasomotor symptoms (VMS), which received its first approval in the UK in July 2025. As a neurokinin-targeted therapy, elinzanetant modulates the activity of hyperactive kisspeptin/neurokinin B/dynorphin neurones to reduce the frequency and severity of VMS, which was demonstrated during the OASIS clinical trials. This article summarizes the milestones in the development of elinzanetant leading to this first approval for the treatment of moderate to severe VMS associated with menopause.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Elinzanetant: First Approval

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月12日

查看全文
  • Arnold Lee

摘要

Elinzanetant (Lynkuet™) is a non-hormonal, small-molecule neurokinin 1 (NK1) and 3 (NK3) antagonist being developed by Bayer for the treatment of vasomotor symptoms (VMS), which received its first approval in the UK in July 2025. As a neurokinin-targeted therapy, elinzanetant modulates the activity of hyperactive kisspeptin/neurokinin B/dynorphin neurones to reduce the frequency and severity of VMS, which was demonstrated during the OASIS clinical trials. This article summarizes the milestones in the development of elinzanetant leading to this first approval for the treatment of moderate to severe VMS associated with menopause.